Media headlines about Exelixis (NASDAQ:EXEL) have trended positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Exelixis earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.5761520592309 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Legal Departments of the Year, Product Counseling, Emerging Companies: Exelixis (finance.yahoo.com)
- Exelixis Inc (NASDAQ: EXEL) – Is the Stock In Play? – Alpha Beta Stock (alphabetastock.com)
- Legal Departments of the Year, M&A, Emerging Companies: Exelixis … – Law.com (law.com)
- Better Buy: Exelixis, Inc. vs. Novartis AG – Nasdaq (nasdaq.com)
Several equities analysts recently weighed in on EXEL shares. Stifel Nicolaus reaffirmed a “hold” rating and set a $26.00 target price on shares of Exelixis in a research note on Tuesday, October 17th. Royal Bank Of Canada raised their target price on shares of Exelixis from $33.00 to $39.00 and gave the company an “outperform” rating in a research note on Tuesday, October 17th. Needham & Company LLC lifted their price objective on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Wednesday, October 18th. Finally, Leerink Swann cut shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $34.00 to $28.00 in a research note on Friday, September 22nd. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $31.38.
Shares of Exelixis (EXEL) opened at $26.05 on Tuesday. The company has a market cap of $7,647.81, a price-to-earnings ratio of 50.69, a PEG ratio of 1.25 and a beta of 1.89. Exelixis has a twelve month low of $14.22 and a twelve month high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.18. The firm had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The business’s revenue was up 145.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.04) EPS. analysts predict that Exelixis will post 0.45 EPS for the current year.
In other Exelixis news, Director Stelios Papadopoulos sold 200,000 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $27.68, for a total transaction of $5,536,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 27,302 shares of the stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $24.28, for a total transaction of $662,892.56. The disclosure for this sale can be found here. Insiders have sold 970,152 shares of company stock valued at $25,923,457 in the last ninety days. Insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.